|
Jul 29
|
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
|
|
Jun 21
|
A US$60m drop in the market cap of Pulse Biosciences, Inc. (NASDAQ:PLSE) is not what insiders like to see after purchasing shares recently
|
|
May 14
|
Pulse Biosciences Enhances Executive Leadership Team
|
|
May 13
|
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2024 Earnings Call Transcript
|
|
May 11
|
Pulse Biosciences Insiders Added US$9.69m Of Stock To Their Holdings
|
|
May 9
|
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
|
|
May 8
|
Q1 2024 Pulse Biosciences Inc Earnings Call
|
|
May 8
|
Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 7
|
Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments
|
|
May 7
|
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
|
|
May 2
|
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
|
|
Apr 24
|
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
|
|
Apr 1
|
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript
|
|
Mar 29
|
Q4 2023 Pulse Biosciences Inc Earnings Call
|
|
Mar 28
|
Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023
|
|
Mar 28
|
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
|
|
Mar 28
|
Pulse Biosciences Announces Plans to Initiate a Rights Offering
|
|
Mar 14
|
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
|
|
Mar 8
|
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
|
|
Jan 31
|
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
|